一 | 中新社上海8月21日电 (记者 姜煜)毕马威21日发布《2026年信托业报告》(下称“报告”)称，截至2025年末，中国信托行业资产规模达34.1万亿元(人民币，下同)，较2023年增长近50%，增速从2023年的12.23%跃升至2025年的25.81%，呈现加速增长态势。 CVS Health is planning to remove one type of a common decongestant from shelves after an advisory committee to the U.S. Food and Drug Administration said it was ineffective earlier this year.The products contain the oral formulation of phenylephrine (PE), which is found in several over-the-counter (OTC) medications.Although PE has been used as a decongestant for nearly a century, experts have been questioning its efficacy for years.The FDA Nonprescription Drugs Advisory Committee unanimously voted in September that PE did not improve nasal congestion any more than a placebo at the dosage given for OTC use.In response, CVS said it is removing products, in which PE is the only active ingredient from store shelves. This means products like Dayquil, which used a combination of active ingredients, will remain available for purchase."We are aware of the FDA Advisory Committee's position on oral phenylephrine (PE) and will follow direction from the FDA to ensure products we sell comply with all laws and regulations," CVS Health said in a statement. "We are removing certain oral cough and cold products that contain phenylephrine as the only active ingredient from CVS Pharmacy stores. Other oral cough and cold products will continue to be offered to meet consumer needs."CVS did not give specifies on brands that will be removed.The FDA told ABC News it has not yet determined whether it no longer considers PE to be a safe and effective medication and has not ordered the product to be removed from shelves. CVS's move is voluntary."The FDA has no further information to provide at this time regarding the timing of any decision the agency may make following the advisory committee meeting," the federal health agency said.The Consumer Healthcare Products Association told ABC News that the advisory committee's recommendation is a non-binding decision and not a change in regulation."FDA is currently in the process of reviewing the regulatory status of oral phenylephrine (PE) following September's advisory committee meeting," CHPA said in a statement. "Until FDA makes a determination on the committee's recommendation, oral PE remains a Category 1 OTC ingredient, which is generally recognized as safe and effective."Concerns were first raised about PE in 2007. Since then, evidence has accumulated showing that the drug offers little to no relief for nasal congestion.Experts believe this is because the body processes the drug before it reaches the nasal passages where it needs to work.It's unclear if other major retail pharmacy chains will follow in CVS's footsteps.Walgreens Boots Alliance would not disclose whether it was planning to remove products with PE from store shelves and said it would defer to the FDA."Walgreens follows FDA regulations. We are closely monitoring the situation and actively partnering with the Walgreens Office of Clinical Integrity and suppliers on appropriate next steps," a Walgreens spokesperson told ABC News.Other major pharmacy chains including Albertsons, Costco and Kroger did immediately reply to ABC News' request for comment. Walmart did not have an answer immediately available.ABC News' Sasha Pezenik and Sony Salzman contributed to this report.。 报告称，在行业整体扩容的同时，市场资源持续向头部公司集中，最直观的特征是万亿级信托公司数量大幅扩容，头部阵营体量走高。2023年仅有4家公司迈入万亿门槛，2024年新增1家；2025年迎来集中扩容，4家信托公司新晋万亿阵营，万亿公司总数达到9家。
二 | 2025年，中国排名前10位的信托公司资产规模进一步增至18.19万亿元，行业占比超过53%，行业资源向头部公司集中的趋势更加明显。 报告分析，头部公司积极响应监管要求，主动收缩高风险业务，提前布局家族信托、资产证券化等主流赛道，主动管理能力持续增强，风险控制优势凸显，合规水平高，在行业风险出清阶段更受机构及高净值客户青睐，资金持续向其集中。 报告指出，2023年至2025年，在回归信托本源、严控通道类业务、强化主动管理能力的行业监管导向下，中国信托行业资产管理结构持续优化，主动管理类信托业务规模稳步扩容、占比持续提升，被动管理类业务占比逐步收缩，行业发展质量显著提升。
Current article:http://0n1.pisezuibanzoukou.cyou/news/20260826_1582857.html
Published on:01:51:54
